| 66.21 Data as of Jun 17 |  -0.09 / -0.14%Today’s Change | 37.52 Today|||52-Week Range 68.62 | +63.60% Year-to-Date |
| US Launch of Forest's Namenda XR - Analyst Blog Jun 17 / Zacks.com | Questcor Surges on Drug Acquisition - Analyst Blog Jun 12 / Zacks.com |
| XOMA Commences Gevokizumab Study - Analyst Blog Jun 17 / Zacks.com | AstraZeneca to Buy Pearl Therapeutics - Analyst Blog Jun 11 / Zacks.com |
| Update on UCB Lupus Candidate - Analyst Blog Jun 13 / Zacks.com | Tentative Approval for SUPN Candidate - Analyst Blog Jun 11 / Zacks.com |
| FDA Panel Meeting for Salix Drug - Analyst Blog Jun 13 / Zacks.com | Salix Rises On Unusually High Volume (SLXP) Jun 11 / TheStreet.com |
| Orphan Drug Status for ViroPharma's Maribavir - Analyst Blog Jun 12 / Zacks.com | Update on Gentium's Defibrotide - Analyst Blog Jun 10 / Zacks.com |
| Previous close | 66.30 |
| Today’s open | 67.01 |
| Day’s range | 66.01 - 67.79 |
| Volume | 407,462 |
| Average volume (3 months) | 551,291 |
| Market cap | $4.1B |
| Dividend yield | -- |
| Earnings growth (last year) | -29.86% |
| Earnings growth (this year) | +7.12% |
| Earnings growth (next 5 years) | +22.50% |
| Revenue growth (last year) | +36.07% |
| P/E ratio | 54.7 |
| Price/Sales | 3.23 |
| Price/Book | 7.20 |
| Today’s change | Today’s % change | |
|---|---|---|
| JAZZJazz Pharmaceuticals... | -1.36 | -1.92% |
| ALKSAlkermes Plc | -0.63 | -2.14% |
| SGENSeattle Genetics Inc | -0.75 | -2.29% |
| ENDPEndo Health Solution... | +0.52 | +1.34% |
| Next reporting date | August 12, 2013 |
| EPS forecast (this quarter) | $0.81 |
| Annual revenue (last year) | $735.4M |
| Annual profit (last year) | $64.2M |
| Net profit margin | 8.74% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Carolyn J. Logan |
Chief Financial Officer & EVP-Administration Adam C. Derbyshire, MBA |
Corporate headquarters Raleigh, North Carolina |
.
